A128940 Stock Overview
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A128940 from our risk checks.
Hanmi Pharm. Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩318,500.00 |
| 52 Week High | ₩377,000.00 |
| 52 Week Low | ₩258,000.00 |
| Beta | 0.52 |
| 11 Month Change | 10.21% |
| 3 Month Change | 12.35% |
| 1 Year Change | 15.00% |
| 33 Year Change | 7.99% |
| 5 Year Change | 25.37% |
| Change since IPO | 410.13% |
Recent News & Updates
Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 16
Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now
Jul 31Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?
Jul 16Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11Recent updates
Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 16Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now
Jul 31Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?
Jul 16Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
May 08Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up
Apr 22Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
Mar 15Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16
What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?
Jan 17Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years
Dec 22Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 24Shareholder Returns
| A128940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.6% | 7.5% | -1.9% |
| 1Y | 15.0% | 17.8% | 0.6% |
Return vs Industry: A128940 underperformed the KR Pharmaceuticals industry which returned 18.2% over the past year.
Return vs Market: A128940 exceeded the KR Market which returned 1.7% over the past year.
Price Volatility
| A128940 volatility | |
|---|---|
| A128940 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A128940 has not had significant price volatility in the past 3 months.
Volatility Over Time: A128940's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 2,273 | Jae-Hyun Park | www.hanmipharm.com |
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
Hanmi Pharm. Co., Ltd. Fundamentals Summary
| A128940 fundamental statistics | |
|---|---|
| Market cap | ₩3.84t |
| Earnings (TTM) | ₩184.38b |
| Revenue (TTM) | ₩1.57t |
21.9x
P/E Ratio2.6x
P/S RatioIs A128940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A128940 income statement (TTM) | |
|---|---|
| Revenue | ₩1.57t |
| Cost of Revenue | ₩693.61b |
| Gross Profit | ₩875.17b |
| Other Expenses | ₩690.79b |
| Earnings | ₩184.38b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.54k |
| Gross Margin | 55.79% |
| Net Profit Margin | 11.75% |
| Debt/Equity Ratio | 41.8% |
How did A128940 perform over the long term?
See historical performance and comparison